Strengthening manufacturing quality and domestic and international regulatory affairs
First written in FY2016. 7 of 13 entries say "Restated". Latest entry: FY2024-Q2.
No other company in this theme has enough history to compare yet.
- FY2024-Q2RestatedAnnual report
「Optimizing supply chain management through appropriate demand forecasting and cost management, improving business processes, and strengthening quality control」
Demand forecasting and cost management, supply chain optimization, business process improvement, and strengthening quality control continue as an integrated initiative. - FY2024-Q1RestatedAnnual report
「Optimizing supply chain management through appropriate demand forecasting and cost management, improving business processes, and strengthening quality control」
Strengthening quality control continues as an integrated initiative with demand forecasting, cost management, supply chain optimization, and business process improvement. - FY2021AdvancedAnnual report
「To maintain product quality, the Group has established a Quality Policy based on its corporate philosophy and conducts planning, manufacturing and procurement, and sales of products for the pharmaceutical and medical device, industrial materials, and stationery and office supplies industries under management centered on initiatives involving its quality management system.」
Quality assurance has been formalized as management centered on the Quality Policy and quality management system and organized as a means of addressing material risks. - FY2020AdvancedAnnual report
「In quality assurance, the Group established a Quality Control Department at its plants, pursues greater reliability, and promotes product quality improvement and enhancement through broad use of market information. It will also strengthen its quality verification functions in the regulatory affairs field in Japan and overseas, allocate appropriate resources for overseas medical device registration, and advance these initiatives.」
The Group specified the establishment of Quality Control Departments at its plants, use of market information, strengthening of regulatory quality verification functions, and allocation of resources to overseas medical device registration as quality assurance measures. - FY2019-Q2RestatedAnnual report
「Against this economic backdrop, in the final year of its medium- to long-term management plan NB100, the Group is working on establishing ¥50 billion corporate quality, developing human resources, and realizing a creative and development-oriented company as its strategic framework.」
The quality agenda continues under the NB100 final-year strategic framework of "Establishing ¥50 billion Corporate Quality." - FY2019-Q1ReframedAnnual report
「Against this economic backdrop, in the final year of its medium- to long-term management plan NB100, the Group is working on establishing ¥50 billion corporate quality, developing human resources, and realizing a creative and development-oriented company as its strategic framework.」
The quality agenda is presented in the NB100 final-year strategic framework as "Establishing ¥50 billion Corporate Quality," replacing the previous expressions focused on manufacturing quality, regulatory affairs, and "¥50 billion Corporate Quality." - FY2018-Q2RestatedAnnual report
「Against this economic backdrop, the Group is pursuing the establishment of ¥50 billion corporate quality, realization of a creative and development-oriented company, and establishment of an optimal business development system as the Stage 3 strategy under its medium- to long-term management plan NB100.」
The quality agenda continues under the Stage 3 strategy of "Establishing ¥50 billion Corporate Quality." - FY2018-Q1ReframedAnnual report
「Against this economic backdrop, the Group is pursuing the establishment of ¥50 billion corporate quality, realization of a creative and development-oriented company, and establishment of an optimal business development system as the Stage 3 strategy under its medium- to long-term management plan NB100.」
The quality agenda has been reorganized from a framework centered on manufacturing quality, regulatory affairs, and corporate quality into the Stage 3 strategic expression, "Establishing ¥50 billion Corporate Quality." - FY2017RestatedAnnual report
「In quality assurance, the Group will pursue higher quality from the customer's perspective, strengthen its system for monitoring manufacturing quality, and focus on further improving quality during development planning and the design stage. It will also strengthen its regulatory affairs functions in Japan and overseas and promote the registration of medical device products in countries around the world.」
The Group continues to prioritize strengthening manufacturing quality, design quality, domestic and international regulatory affairs functions, and overseas medical device registration. - FY2017-Q3RestatedAnnual report
「Against this economic backdrop, as the first year of Stage 3, the final three-year plan under the Group's medium- to long-term management plan NB100, the Group worked on executing a business growth strategy through customer-focused proactive expansion initiatives and the creation of new value; establishing an optimal group-wide production system aimed at consolidated sales of ¥50 billion; developing globally competitive human resources and improving quality across the Group to establish corporate quality; and strengthening corporate governance.」
Quality initiatives are continuing as Stage 3 priority measures focused on corporate quality, talent development, and improving quality across the Group. - FY2017-Q2RestatedAnnual report
「Against this economic backdrop, as the first year of Stage 3, the final three-year plan under the Group's medium- to long-term management plan NB100, the Group worked on executing a business growth strategy through customer-focused proactive expansion initiatives and the creation of new value; establishing an optimal group-wide production system aimed at consolidated sales of ¥50 billion; developing globally competitive human resources and improving quality across the Group to establish corporate quality; and strengthening corporate governance.」
Quality initiatives are continuing as Stage 3 priority measures focused on corporate quality, talent development, and improving quality across the Group. - FY2017-Q1ReframedAnnual report
「Developing globally competitive talent and improving quality across the Group to establish corporate quality」
The quality agenda is presented not only in terms of manufacturing quality and regulatory affairs, but also as a framework for establishing corporate quality and improving quality across the Group. - FY2016First statedAnnual report
「In quality assurance, the Group will pursue higher quality from the customer's perspective, strengthen its system for monitoring manufacturing quality, and focus on further improving quality during development planning and the design stage. It will also strengthen its regulatory affairs functions in Japan and overseas and promote the registration of medical device products in countries around the world.」
Quality monitoring, quality improvement at the design stage, regulatory affairs functions, and overseas medical device registration are being addressed as an integrated set of issues.